Middle East & Africa Blood Transfusion Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product, Application, and End User

The MEA blood transfusion diagnostics market is expected to grow from US$ 151.99 million in 2022 to US$ 199.02 million by 2028. It is estimated to grow at a CAGR of 4.6% from 2022 to 2028.

Blood transfusion diagnostics are usually deployed during long-hour surgeries, such as kidney transplants, and in cases of emergencies. These surgeries are associated with the chances of excessive blood loss, which makes it difficult to make up for the blood loss with new blood, especially in the case of rare blood groups. Due to the ample demand, key players in the blood transfusion diagnostics market are offering advanced and fully automated blood transfusion diagnostics that reduce human interventions. For instance, in April 2019, BD launched its BD BACTEC quality control media to help identify contaminated platelet units during transfusions. Many companies employ strategic activities, such as acquisitions and partnerships, to capture better shares in the market. In December 2019, Getinge purchased Applikon Biotechnology, a leader in the development and supply of innovative bioreactor systems suitable for all scales, ranging from laboratory to industrial. In October 2019, Medtronic acquired AV Medical Technologies. Such advancements are likely to bring new trends in the blood transfusion diagnostics market in the coming years.

Market Overview

In 2021, South Africa held the largest share of the blood transfusion diagnostics market in the MEA. The country records the increasingly high incidence of various chronic diseases, such as diabetes, cancer, cardiovascular, and infectious diseases, requiring surgical procedures as a treatment. Also, healthcare facilities in South Africa are developing and adopting the latest technologies to offer better treatments. An article titled "Improving Sepsis Care in Africa, 2021" estimated that ~85% of sepsis cases occur in low and middle-income countries, with the highest burden in Africa. In addition, children (especially newborns), pregnant women, and elderly people are the most affected population. In Africa, ~17 million cases and 3.5 million deaths occurred in 2017 due to sepsis. Further, the increasing cases of sickle cell anemia (SCD) and thalassemia in South Africa are likely to complement the blood transfusion diagnostics market in South Africa. According to data published in Pan African Medical Journal, the World Health Organization (WHO) estimates ~50 million people with sickle cell trait globally, with the cases reaching 38 million in sub-Saharan Africa; Africa has 500,000 children with sickle cell disease, and 70% die before they turn 5 years of age, due to the lack of adequate care. SCD patients frequently require a blood transfusion, which can be associated with the increased demand for blood transfusion diagnostics in the country.

MEA Blood Transfusion Diagnostics Market Segmentation

The MEA blood transfusion diagnostics market is segmented based on product, application, end user, and country.

• Based on product, the MEA blood transfusion diagnostics market is bifurcated into instruments & kits and reagents. The instruments & kits segment held the larger market share in 2022.
• Based on application, the MEA blood transfusion diagnostics market is bifurcated into blood grouping and disease screening. The disease screening segment held the larger market share in 2022.
• Based on end user, the MEA blood transfusion diagnostics market is segmented into hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood banks segment dominated the market in 2022.
• Based on country, the MEA blood transfusion diagnostics market has been categorized into the UAE, Saudi Arabia, South Africa, and Rest of the MEA. Our regional analysis states that South Africa dominated the market in 2022. Abbott; BAG Diagnostics GmbH; Bio-Rad Laboratories, Inc.; DiaSorin S.p.A.; F. Hoffmann-La Roche Ltd; Grifols, S.A.; Immucor, Inc.; Ortho Clinical Diagnostics (QuidelOrtho Corporation); Quotient Limited; and Thermo Fisher Scientific Inc. are the leading companies operating in the MEA blood transfusion diagnostics market.